Clinical Trial Detail

NCT ID NCT03512197
Title A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Daunorubicin + Midostaurin

Cytarabine + Idarubicin + Midostaurin

Cytarabine + Idarubicin

Daunorubicin

Age Groups: senior adult

Additional content available in CKB BOOST